Pladgett to Head Biotech Group at GCI
Charting the future of public relations
Holmes Report
CEO

Pladgett to Head Biotech Group at GCI

Mark Padgett, a financial communications professional with over six years experience in the biotechnology and pharmaceutical industries, has joined GCI Group as vice president of biotechnology for the firm’s investor relations practice.

Paul Holmes

NEW YORK, August 22—Mark Padgett, a financial communications professional with over six years experience in the biotechnology and pharmaceutical industries, has joined GCI Group as vice president of biotechnology for the firm’s investor relations practice. He will be responsible for enhancing the agency’s financial expertise in biotechnology to complement GCI’s industry-leading healthcare practice.
 
“At a time when our healthcare practice is booming, Mark’s addition to the investor relations team will strengthen collaboration between the two practices,” said Tom Reno, president of GCI New York.  “His deep science background combined with his understanding of Wall Street will enable him to drive our financial capabilities in this sector.”
 
Padgett was previously a manager at Life Sciences Consulting, where he created and implemented IR programs for biotechnology and pharmaceutical companies. Prior to that, he worked in new product development for Johnson & Johnson in Mexico City and was as a research specialist for the department of medicine at the Medical University of South Carolina in Charleston.
View Style:

Load 3 More
comments powered by Disqus